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Background: In 2009, a novel influenza A/H1N1 virus (H1N1pdm) quickly spread worldwide and co-circulated with
then-existing seasonal H1N1 virus (sH1N1). Distinguishing between these 2 viruses was necessary to better
characterize the epidemiological properties of the emergent virus, including transmission patterns, pathogenesis,
and anti-influenza drug resistance. This situation prompted us to develop a point-of-care virus differentiation system
before entering the 2009–2010 influenza season. Aiming to establish H1N1pdm-specific detection tools rapidly, we
employed phage display libraries to select H1N1pdm-specific single-chain variable fragments (scFvs).
Findings: Human single-fold scFv libraries (Tomlinson I + J) underwent selection for the ability to bind H1N1pdm
virus particles. Three rounds of panning brought 1152 phage-bound scFvs, of which 58 clones reacted with
H1N1pdm specifically or preferentially over sH1N1 in an enzyme-linked immunosorbent assay (ELISA). After
conversion of the scFvs to soluble form, 7 clones demonstrating high/stable expression were finally obtained.
However, all the soluble scFvs except No. 29 were found to have lost their specificity/preference for H1N1pdm in
ELISA. The specificity/preference of No. 29 was also confirmed by immunofluorescence assay and
immunoprecipitation, and the viral nucleoprotein was identified by ELISA as its target protein. The change in
specificity associated with scFv conversion from phage-bound to soluble form could be due to loss of phage
scaffold pIII protein, which likely provides structural support for the scFv antigen-binding site. It is also possible that
the similar antigenic properties of H1N1pdm and sH1N1 led to the observed alterations in scFv specificity.
Discussion: Using a phage display library, we obtained 7 soluble scFv clones reactive against H1N1pdm; however,
only 1 showed specificity/preference toward H1N1pdm. Our results confirmed that using phage display libraries
was highly advantageous for the rapid development of molecules to detect target antigens. However, our results
also indicated that this strategy might not have been effective for selecting H1N1pdm-specific antibodies during
the 2009 pandemic, where the co-circulating sH1N1 virus shared similar antigenic properties. This suggests that it
might be advisable to use a synthetic scFv phage display library by strategically considering the characteristics of
target antigens and the potential situations.
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Background
The periodic occurrence of influenza type A virus with
novel antigenic properties, also known as a pandemic,
has posed serious threats to the human population.
Aiming to mitigate the disease burden posed by pan-
demics, various studies have investigated topics ranging
from predictions of the potential subtypes that will cause
the next pandemic [1] to the development of specific
diagnostic tools and prepandemic vaccines [2]. These
studies mainly targeted highly pathogenic avian influ-
enza (HPAI) viruses typified by the H5N1 subtype [3]. In
2009, a novel influenza A/H1N1 virus (H1N1pdm)—a
triple reassortant of “swine-origin” viruses [4]—emerged
in Mexico and quickly spread across the globe. Co-
circulation of H1N1pdm and then-existing seasonal
H1N1 virus (sH1N1) created a need for distinguishing
these viruses in clinical settings to better understand the
pattern of transmission and pathogenesis of H1N1pdm
[5]. Distinguishing between these viruses was also crit-
ical to choosing appropriate anti-influenza drugs, as the
majority of sH1N1 in Japan, had acquired resistance
against the orally active neuraminidase inhibitor oselta-
mivir by 2009 [6]. This situation prompted us to rapidly
develop a point-of-care testing system during the brief
time available before entering the 2009–2010 influenza
season to differentiate H1N1pdm from sH1N1.
Immunochromatography (IC) has been routinely used
in point-of-care rapid detection systems against seasonal
influenza viruses. However, ICs that were commercially
available at the onset of the 2009 pandemic, which tar-
geted nucleoproteins (NPs), had been found not to dis-
tinguish between these 2 viruses. The development of IC
designed to specifically detect H1N1pdm would be
feasible if we could obtain an agent that specifically
detected H1N1pdm but not sH1N1. Establishment of
monoclonal antibodies was 1 option; however, this pro-
cedure requires animal immunization, which takes sev-
eral months. We therefore decided to use phage display
libraries to select H1N1pdm-specific single-chain vari-
able fragments (scFvs). An scFv is an antigen-binding
protein that consists of the VH and VL regions of the vari-
able antigen-binding sites of immunoglobulin, connected
by a short linker sequence. We anticipated that specific
scFvs could be selected in a minimum of less than
3 weeks using scFv phage display libraries.
In this article, we will describe the H1N1pdm-reactive
scFvs obtained and the unexpected observation that
most scFvs altered their specificity and cross-reacted
with sH1N1 after conversion from the phage-bound to
soluble form. Relating these findings to the antigenic
resemblance between H1N1pdm and sH1N1, we will
discuss the importance of strategically selecting the
methods used for developing diagnostic tools dependingon the characteristics of the emerging virus, particularly
under the time pressure posed by pandemics.
Results
Initial screening of phage-bound scFvs against H1N1pdm
In this study, human single-fold scFv libraries I + J
(Tomlinson I + J; a kind gift from MRC Centre for Pro-
tein Engineering, Cambridge, United Kingdom) under-
went selection for the ability to bind H1N1pdm virus
particles. After 3 rounds of panning, a total of 1152 indi-
vidual Escherichia coli TG1 clones (576 clones each from
Tomlinson I and J) were obtained and grown in 96-well
U-bottom plates. From these E. coli TG1 clones, mono-
clonal phage were produced by adding KM13 helper
phage to each well.
The binding of these monoclonal phage to immobi-
lized H1N1pdm viral particles was subsequently investi-
gated using enzyme-linked immunosorbent assay
(ELISA). sH1N1 particles and proteins derived from the
allantoic fluid of mock-infected eggs (AF proteins) were
used as control antigens. Among the 1152 phage tested,
58 phage clones (31 and 27 clones from Tomlinson I
and J, respectively) reacted with H1N1pdm specifically
or preferentially in 2 independent ELISA trials (data not
shown). All 58 of these clones were found to be unreact-
ive with AF-protein wells, indicating that non-specific
binding to AF proteins or skim milk (in blocking solu-
tion) was unlikely to occur in these clones. In order to
select genetically independent phage clones, the phage-
mid vector pIT2 was isolated from the respective phage
and the encoded scFv genes were sequenced as
described elsewhere [7]. Consequently, these clones were
found to comprise 42 genetically independent clones (15
and 27 clones from Tomlinson I and J, respectively).
Production of soluble scFvs and specificity confirmation
Using these 42 phage clones, expression and purification
of soluble scFvs was conducted. Expression levels of re-
spective soluble scFv was confirmed by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE),
and we finally obtained 7 soluble clones that demon-
strated high and stable expression in 2 independent ex-
pression trials (5 and 2 clones from Tomlinson I and J,
respectively) (data not shown). These soluble scFvs were
next subjected to ELISA against immobilized H1N1pdm
and sH1N1. It was a surprise to find that 6 clones (Nos.
4, 21, 25, 27, 34, and 46) lost their specificity/preference
toward H1N1pdm and showed equivalent reactivity
against both viruses or even a slight preference toward
sH1N1 (Figure 1). On the other hand, only 1 clone
(No. 29 from Tomlinson I), maintained its preference
toward H1N1pdm. In 2 independent ELISA trials, the
same results were obtained. The reactivity of No. 29
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Figure 1 Comparison of binding of respective soluble scFv
against H1N1pdm and sH1N1 particles by ELISA. To compare
the binding ability of soluble scFv against H1N1pdm and sH1N1,
ELISA was performed against each immobilized antigen in 2
independent trials. The ratio of OD450 against sH1N1 versus
H1N1pdm is shown. Values are mean ± SE; N = 2.
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a preference toward H1N1pdm (Figure 2), the other 6
clones reacted with both viruses equally (data not
shown).
Further characterization of the soluble scFv clones
To further characterize these 7 clones, with particular
focus on No. 29, we attempted to identify viral proteins
recognized by each scFv. First, hemagglutination inhib-
ition (HI) and neutralization tests were performed to in-
vestigate whether these scFvs recognized envelope
proteins. Neither HI nor neutralizing activity was
observed (data not shown). Next, ELISA against purified
H1N1pdm nucleoprotein (NP) was performed. Two
clones, Nos. 29 and 46, were found to react with NP
(Figure 3A). To confirm the reactivity of No. 29 against
NP, immunoprecipitation was conducted against the
lysates of MDCK cells infected with H1N1pdm or
sH1N1 and mock-infected cells. As shown in Figure 3B,
No. 29 reacted with a 56 kDa protein in the lysate of100µm
H1N1pdm sH1N
Figure 2 Reactivity of soluble scFv No. 29 against H1N1pdm-, sH1N1-
sH1N1-, and mock-infected MDCK cells was performed to examine the abil
using 3.6% formaldehyde and 0.4% Triton-X, 1.25 μg of scFv No. 29 was ad
anti-mouse IgG.H1N1pdm-infected cells only. Based on the molecular
weight, this protein was assumed to be NP.
Discussion
In this study, scFvs against pandemic influenza type A
virus from a phage display library were selected in order
to generate an H1N1pdm-specific detection tool as
quickly as possible before entering the first influenza
season after emergence of the virus.
In the initial screening of phage-bound scFvs, we
obtained a total of 58 clones that bound specifically to
H1N1pdm or preferentially to H1N1pdm over sH1N1.
After conversion to the soluble form, 7 genetically inde-
pendent clones demonstrating high and stable expres-
sion were finally selected. Unexpectedly, 6 of the 7
soluble scFv clones were found to have lost their prefer-
ence/specificity toward H1N1pdm (Figure 1). Interest-
ingly, this change in specificity of scFvs after conversion
from the phage-bound to soluble form has been previ-
ously described; Goswami et al. [8] reported the altered
specificity of scFvs while attempting to isolate scFv spe-
cific to the placental isozyme of alkaline phosphatase
(PLAP) using Tomlinson’s phage display library. Several
clones that had been specific to PLAP in phage-bound
form were observed to become cross-reactive with very
closely related bone alkaline phosphatase isozymes after
conversion to the soluble form. The authors speculated
that this alteration in specificity was due to the loss of
phage scaffold pIII protein associated with the produc-
tion of soluble scFv. Because this protein has a role in
anchoring scFv to the phage surface, they suggested that
pIII might provide indirect structural support for the
formation of the scFv antigen-binding site. Their obser-
vations provide a likely explanation for our results as
well. A lack of structural support by pIII could account
for the loss of scFv specificity against H1N1pdm in most
clones after conversion from the phage-bound to soluble
form. It is also possible that the similarity in antigenic
properties shared by target proteins from identical sub-
types of influenza A virus, H1N1pdm and sH1N1, could100µm 100µm
mock1
, and mock-infected MDCK cells in IFA. IFA against H1N1pdm-,
ity of soluble scFv No. 29 to bind virus. Following fixation of the cells
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Figure 3 A) Comparison of binding of respective soluble scFv against H1N1pdm and sH1N1 particles by ELISA. To compare the binding
ability of soluble scFv against purified H1N1pdm NP, ELISA was performed against each immobilized antigen in duplicate. N.C. represents
negative control (soluble scFv against rabies virus phosphoprotein). P. C. indicates positive control (serum of H1N1pdm-infected ferret). Values are
mean ± SE; N = 2. B) Identification of the target protein of scFv No. 29 by immunoprecipitation and SDS-PAGE. The lysates of H1N1pdm/
sH1N1-infected and mock-infected MDCK cells were immunoprecipitated with soluble scFv No. 29 followed by SDS-PAGE analysis and silver staining.
Lysate origins include H1N1pdm-infected cells (P), sH1N1-infected cells (S), and mock-infected cells (Mo). C1 and C2 indicate negative control
reactions; only the lysate of mock-infected cells (C1) and the soluble scFv fluid (C2) were subjected to magnetic beads before following the same
procedure as described for the other samples. ‘MW’ indicates a protein molecular weight marker. Filled arrow corresponds to the 56 kDa protein,
presumably NP. Empty arrow denotes soluble scFvs. Other bands were considered to be non-specific binding of unrelated proteins.
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quency observed in our study. A similar phenomenon
was also reported recently in another study using
Tomlinson’s phage display library. Chan et al. [9]
observed the loss of specificity of scFvs against the pro-
tective antigen toxin component of Bacillus anthracis
during conversion from phage-bound to soluble form.
Considering several independent studies have produced
comparable results using different antigens, there is a
possibility that this poor convertibility of scFvs was not
particular to the antigen used (such as influenza viruses)
but inherent in this library.
Our strategy, panning on immobilized viruses, has
been used in several previous studies [10,11] and con-
tributed to the expedition of the whole selection process
by eliminating the need to purify specific target antigens.
We had originally expected that the use of purified viral
particles as an immobilized antigen for panning would
isolate scFvs against envelope proteins, which could
overcome the inability of the then-used point-of-care
ICs using anti-NP antibodies to differentiate H1N1pdm
from sH1N1; NPs possess important antigenic differ-
ences that enable influenza viruses to be distinguished
into 3 genera (influenza virus A, B, and C); however,
NPs are highly conserved within each genus. On the
other hand, HA genes are one of the most specific genes
in the influenza virus genome, and viral RNA analysis
targeting HA genes was conducted for specific detectionof H1N1pdm in clinical specimens during the 2009 pan-
demic [12]. However, contrary to our expectations,
among the 7 clones finally established, the target pro-
teins of 2 scFv clones were identified as NP. Further in-
vestigation is needed to identify the target proteins of
the other 5 clones. Although it remains unclear why
anti-NP scFvs were selected, it was likely that some viral
components had been exposed during the preparation of
viral particles. In fact, during and after the 2009 pan-
demic, the development of several ICs, which can differ-
entiate these 2 viruses were reported. These ICs target
NP [13,14] or/and HA [13], and the NP-based system
appeared to be superior to the HA-based system in
terms of specificity and sensitivity [13]. This indicates
that targeting NP, instead of envelope proteins, might
have increased the possibility of obtaining H1N1pdm-
specific scFvs in our study. However, considering the
altered specificity of the scFvs observed in this study and
in several previous studies [8,9], our unexpected results
can be attributed to using a synthetic scFv phage display
library rather than purified viral particles as an immobi-
lized antigen for panning to target envelope proteins.
Since the 2009 pandemic, H1N1pdm has remained
prevalent and is expected to replace sH1N1. Various
studies have been conducted in anticipation of the next
pandemic. Such research is important to prepare for
the appearance of unexpected subtype strains that have
the potential to become pandemic. As in the 2009
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ment of specific diagnostic tests or a vaccine in an ex-
tremely short period of time. Success would require
that limited resources for research be allocated stra-
tegically, prudently, and according to feasibility. Our
findings indicate that the use of a synthetic scFv phage
display library might not necessarily be effective in
every situation. Nevertheless, considering its remarkable
rapidity in producing specific antibodies, it should be
noted that this strategy could be highly advantageous
in more suitable situations where a novel virus pos-
sesses distinct antigenic properties. Employing and
combining appropriate strategies according to the char-
acteristics of the emerging virus is essential for rapid
development of diagnostic tools and mitigating the bur-
den posed by a pandemic.
Methods
Viruses and cells
Two strains of Influenza type A virus were used in this
study: a 2009 pandemic strain, A/Narita/1/2009(H1N1)
(referred to as “H1N1pdm”) and a seasonal influenza
strain (2009), A/Brisbane/59/2007(H1N1) (referred to as
“sH1N1”). These viruses were propagated in fertilized
hens’ eggs. MDCK cells derived from canine kidney were
used for investigating the interaction between scFvs and
viral proteins by indirect fluorescent assay and immuno-
precipitation (details follow).
Virus purification
Viral particles were purified from the AF of virus-
infected fertilized hens’ eggs using Cellufine Sulfate
(Chisso, Tokyo, Japan) following AF collection 48 h after
inoculation. Briefly, after the Cellufine Sulfate gel was
equilibrated with 0.01 M phosphate buffer (PB) (pH 7.4),
the AF was mixed with the gel using a rotator for 1 h at
room temperature. After washing 4 times in washing
buffer (0.01 M PB, 0.19 M NaCl [pH 7.2]), viral particles
were eluted with elution buffer (0.01 M PB, 3 M NaCl
[pH 7.0]). The HA titer of each preparation was mea-
sured after every purification trial. As a negative control,
AF from mock-infected eggs underwent the same pro-
cedure as above, and the eluted sample was referred to
as “AF proteins”.
scFv phage display library
Human single-fold scFv libraries I + J (Tomlinson I + J;
a kind gift from MRC Centre for Protein Engineering,
Cambridge, United Kingdom) underwent selection for
the ability to bind H1N1pdm viral particles. The libraries
are based on a single human framework for VH (V3-23/
DP-47 and JH4b) and Vκ (O12/O2/DPK9 and Jκ1) with
side chain diversity incorporated into positions in the
antigen-binding site. The scFv genes in the libraries arelinked to a His-tag followed by a myc tag and cloned
into pIT2 phagemid vectors.
Selection of phage-bound scFvs
The selection or panning process was essentially as
described in the manufacturer’s protocol [15]. Briefly, 3
Nunc immunotubes (Thermo Fisher, Wiesbaden,
Germany) were coated overnight with 4 mL of a 1:10 di-
lution of the following antigens: i) H1N1pdm, ii) sH1N1,
and iii) AF proteins. After washing with phosphate-
buffered saline (PBS) and blocking with PBS containing
2% (w/v) skim milk, tubes were loaded with 1012 to 1013
phage in the first round of panning. In order to pre-
exclude the phage reactive toward AF proteins or
sH1N1, the phage were first applied to an AF-
protein–coated tube and incubated for 2 h. Unbound
phage were transferred to a sH1N1-coated tube, treated
likewise, and finally reacted with an H1N1pdm-coated
tube in the same manner. After intensive washes, bound
phage were eluted by adding 500 μL of trypsin-PBS
(2 mg/mL trypsin in PBS). The eluted phage were propa-
gated and amplified in E. coli TG1. A total of 3 rounds
of panning was conducted. For the second and third
rounds of panning, only the H1N1pdm-coated tube was
used.
ELISA
For initial screening of phage-bound scFvs, the ELISA
plate was coated overnight with either H1N1pdm or
sH1N1 or AF proteins. The amount of viruses coated
were standardized to the same HA titer of 16 HA units
per well. AF proteins were prepared by diluting AF of
mock-infected eggs at the same dilution as the
H1N1pdm preparation that had a lower HA titer. Non-
specific binding was blocked using PBS containing 5%
(w/v) skim milk. The phage (diluted 1:10) were added to
a set of 3 wells coated with the respective antigen, and
the ELISA plates were incubated for 1 h at room
temperature. After the plates had been washed, the
bound phage were visualized by the addition of horse-
radish peroxidase (HRP)-conjugated protein L (Pierce,
Rockford, IL, USA) and SureBlue TMB 1-component
Microwell Peroxidase Substrate (KPL, Gaithersburg,
MD, USA). For the screening of soluble scFvs, the ELISA
plate was coated with H1N1pdm and sH1N1. The sol-
uble scFvs at a concentration of 8 μg/well were added to
a set of 2 wells coated with the respective antigen, and
the above procedure was followed. The optical density
(OD) was read at 450 nm using a Model 680 Microplate
Reader (Bio-Rad, Hercules, CA, USA). The cut-off
OD450 was set at 0.6 against H1N1pdm. The OD ratio
data was graphed using Prism 5 (GraphPad, San Diego,
CA, USA). For the binding assay of soluble scFvs against
H1N1pdm NP, 2 μg/well of purified NP (a kind gift from
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Diseases) was coated onto the ELISA plate. Soluble scFvs
at a concentration of 8 μg/well were added in duplicate,
and the above procedure was followed. As a negative
control, the same amount of a soluble scFv against ra-
bies virus phosphoprotein [7] was used. As a positive
control, 1:20 diluted H1N1pdm-infected ferret serum (a
kind gift from Dr. T. Odagiri, National Institute of Infec-
tious Diseases) was used.
Phagemid DNA sequencing
The phagemid vector pIT2 was isolated using a
Qiagen Plasmid Midi Kit (Qiagen, Venlo, Nether-
lands). The phagemids were sequenced using the Big
Dye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA) with the 373 DNA
Sequencer (Applied Biosystems). The primers used to
sequence the scFv inserts in the pIT2 vector were
LMB3 (5'-CAGGAAACAGCTATGAC-30) and pHEN
(50-CTATGCGGCCCCATTCA-30). Deduced amino
acid sequences of each scFv were aligned using
GENETYX Ver. 9 (Genetyx, Tokyo, Japan).
Production of soluble scFvs
Expression and purification of soluble scFvs were per-
formed as described elsewhere [7]. Briefly, E. coli
HB2151 cells were infected with these phage, and pro-
tein expression was induced by adding 1 mM isopropyl-
β-D-thiogalactapyranoside to the culture. After purifica-
tion of soluble scFvs using Ni-NTA nickel-charged resin
(Qiagen, Venlo, Netherlands), SDS-PAGE was performed
to confirm the expression of scFvs.
IFA
MDCK cells were infected with H1N1pdm and sH1N1
independently. After 48 h, the cells were fixed in 3.6%
formaldehyde with/without 0.4% Triton-X. Ten or
1.25 μg of each soluble scFv was added and stained using
anti-myc tag mouse MoAb (MBL, Nagoya, Japan) as the
primary antibody and an FITC-goat anti-mouse IgG (H
+ L) (Invitrogen) as the secondary antibody. Cells were
visualized, and the images were digitally captured using
a BZ-8000 “Bio-zero” fluorescence microscope (KEY-
ENCE, Osaka, Japan).
Immunoprecipitation
To identify the target protein of scFv No. 29, immuno-
precipitation of soluble No. 29 against virus-infected
MDCK cells was performed. Briefly, MDCK cells were
grown as a monolayer in 6-well plates, infected with
H1N1pdm or sH1N1 at a multiplicity of infection of 10,
and subsequently incubated in a 5% CO2 incubator.
After 48 h, the cells were lysed with 0.5 mL of lysis buf-
fer (50 mM sodium phosphate [pH 8.0], 300 mM NaCl,0.01% [vol/vol] Tween-20, 1% [vol/vol] Triton-X 100) at
4°C for 1 h. The cell lysates were centrifuged at 20
000 × g for 30 min at 4°C. The supernatants were col-
lected and reacted with 2.5 μg of scFvs for 1 h at 4°C.
The antigen-scFv complexes were immunoprecipitated
using magnetic beads (Dynabeads TALON; Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s proto-
col. The eluted samples were subjected to SDS-PAGE
and silver stained using EzStain Sliver (ATTO, Tokyo,
Japan) according to manufacturer’s protocol.
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